DR. CAMERON DURRANT
Dr. Cameron Durrant is the Chairman and Chief Executive Officer of KaloBios, since March 1, 2016. He was elevated to that position after serving on the board of directors starting January 7, 2016. Dr. Durrant’s expertise and business career has revolved around transformations, whether for brands, business units, or small companies. He has particular therapeutic experience in infectious diseases, pediatrics and oncology – coupled with experience as a practicing physician.He has served as board chairman, lead independent director and as CEO for ... more.
DR. COLIN FORSYTH,
Chagas Epidemiologist , DNDi North America
Colin is an epidemiologist and medical anthropologist who lived in Bolivia in the 1990s and became acquainted with the devastating impact of Chagas disease while there. His dissertation focused on the sociocultural dimensions of Chagas disease in Bolivia. He conducted research in 2013 at a nonprofit clinic in Bolivia where more than half of the patient population was infected with T. cruzi. He investigated the beliefs, experiences, and treatment strategies of patients affected by Chagas disease, and identified key barriers that hampered access to healthcare. His research won a prize from the Society for Applied Anthropology and has been published in Social Science and Medicine. Previously, Colin participated in epidemiological research on access to recommended treatment for heart disease in Florida hospitals. In 2009, he was involved in a project at the Florida Mental Health Institute which documented mental health practices designed for Latinos in different areas of the U.S. He completed an M.P.H in Epidemiology in 2011, and a Ph.D. in Applied Anthropology in 2014, at the University of South Florida, Tampa.
DR. SHEBA MEYMANDI
Director of the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center
Dr Meymandi is the director of the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, in Sylmar, CA, which opened in 2007 as the first US clinic for the diagnosis and treatment of Chagas disease. The Center has since diagnosed and treated over 50 patients and conducts free comprehensive mobile medical evaluations in a grassroots effort to educate about the disease and to detect cases early. It also performs important clinical research into rates of prevalence, conduction abnormalities, pregnant women, and congenital transmission. Such research aims in part to identify potential markers for those at risk of sudden death due to Chagas. Dr Meymandi is a Clinical Professor of Medicine at UCLA’s ... more.
DR. EDWARD L. D'ANTONIO
Assistant Professor of Biochemistry and Structural Biology
University of South Carolina Beaufort
His team consists of undergraduate researchers that utilize a variety of techniques, including: analytical chemistry, biotechnology, enzymology, structural biology, and synthetic chemistry. He uses structure-based drug design methodology to develop new classes of competitive inhibitors for enzyme drug-targets found in parasites of trypanosomatid diseases. These diseases include Chagas' disease (Trypanosoma cruzi), human African trypanosomiasis (Trypanosoma ... more.
DR. YAGAHIRA ELIZABETH CASTRO SESQUEN
Johns Hopkins Bloomberg School of Public Health
DR. MONICA MIRANDA SCHAEUBINGER
Johns Hopkins Bloomberg School of Public Health
Mónica Miranda Schaeubinger coordinates a research project on Chagas disease as part of Dr. Robert Gilman’s team, at the International Health Department of the Johns Hopkins School of Public Health, where she recently completed a MSPH. She is a physician from the National Autonomous University of Mexico and her research interests include pediatrics, infectious disease and underserved populations. More specifically, her current work seeks to ascertain the seroprevalence of Chagas disease in pregnant women of Latino origin in Baltimore to elucidate the subsequent effects of Chagas on pregnancy.
Assistant Director for ProMED at the International Society for Infectious Diseases
Maja (Malwina) Carrion, MPH is the Assistant Director for ProMED at the International Society for Infectious Diseases and serves as a Deputy Module Organizer and Distance Learning Tutor at the London School of Hygiene and Tropical Medicine. She is also currently a DrPH student at Boston University where her dissertation work will focus on Chagas disease epidemiology and
screening in the United States, with an emphasis on Massachusetts.
Maja holds an MPH from Boston University in International Health and a BA from Elon University in Political Science and International Studies. For over 10 years, Maja has led and managed public health projects and research in Asia, Africa, South America, Europe, and the US.
Her primary research interests are innovative infectious disease screening and treatmentprograms, disease and vector control, and neglected tropical diseases.
Corporate Affairs &Communications Regional Head Latin America and Canada (LACan)
Antonio Arce is an international business executive with a career of over 15 years of outstanding achievements in key multinational companies. He has worked across an extensive range of markets and cultures such as US, EU, Singapore,Peru and most recently Mexico.
Antonio has a solid background in obtaining results through a focus on win-win collaborative initiatives where he always places his partner at the forefront of any negotiation. He has also focused on major improvements in productivity and cost- effectiveness in his regional positions and in the operations of the countries of which he oversaw. This successful track record makes him a key contributor for the Novartis Group.
He is currently responsible for the Regional Corporate Affairs and Communications strategies for Novartis Pharmaceuticals in Latin America and Canada; he oversees the corporate external engagement of the company with other economic, political and social agents that are active in driving better health outcomes.
Previous to his current role, Antonio was the Corporate Affairs Head for Novartis Mexico. Antonio joined Novartis in 2009 in the area of Supply Chain and Logistics for Latin America. He holds a Bachelor Degree in Economics, Marketing and Management Information Systems from Florida International University, and also holds a certificate in International Trade and Logistics from California State University.
Dr.Luis Filipe Delgado
Chief Scientific Officer – Novartis Brazil
Luis Filipe is a senior executive with a proven success in business and healthcare sectors (Medical Practice, Medical Education, Consultancy and Pharma segments). He has deep knowledge of the Pharma and Healthcare market from the physician and industry perspective with more than 20 years’ experience leading and managing cross-functional, multi-cultural matrix and non-matrix teams in all aspects of Clinical Development and Medical Affairs at country, region and global level.
He currently leads the Medical organization in Brazil with the highest standards of quality and compliance. He is a Member of the Pharma Executive Committee (PEC) Luis Filipe joined Novartis in 2013. Previously, he worked for Eli Lilly, Bristol Myers Squibb, Public and Private Hospitals He has a Medical Degree from Rio de Janeiro State University,Internal Medicine from Rio de Janeiro Federal University and holds an MBA from Warwick University.
Peter J. Hotez, M.D., Ph.D. is President of the Sabin Vaccine Institute and Dean of the National
School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology
at Baylor College of Medicine where he is also the Texas Children’s Hospital Endowed Chair of Tropical Pediatrics.
Dr. Hotez is an internationally-recognized physician-scientist in neglected tropical diseases and
vaccine development. He leads the only product development partnership for developing new vaccines for hookworm infection, schistosomiasis, and Chagas disease, and SARS/MERS, diseases affecting hundreds of millions of children and adults worldwide. In 2006 at the Clinton Global Initiative he co-founded the Global Network for Neglected Tropical Diseases to provide access to essential medicines for hundreds of millions of people
He obtained his undergraduate degree in molecular biophysics from Yale University in 1980 (phi beta kappa), followed by a Ph.D. degree in biochemistry from Rockefeller University in 1986,
and an M.D. from Weil Cornell Medical College in 1987.
Dr. Hotez has authored more than 400 original papers and is the author of the acclaimed Forgotten People, Forgotten Diseases (ASM Press) and the recently released Blue Marble Health: An Innovative Plan to Fight Diseases of the Poor amid Wealth (Johns Hopkins University Press).
Dr. Hotez served previously as President of the American Society of Tropical Medicine and Hygiene and he is founding Editor-in- Chief of PLoS Neglected Tropical Diseases. He is an elected member of the National Academy of Medicine (formerly the Institute of Medicine – IOM), and in 2011 he was awarded the Abraham Horwitz Award for Excellence in Leadership in Inter-American Health by the Pan American Health Organization of the WHO. In 2014 the White House and U.S. State Department selected Dr. Hotez as its United States Science Envoy.
Prof. Jeffrey L. Moe, Ph.D.
Professor of the Practice in Global Health
Duke Global Health Institute, Duke University
Moe was co-author and principal investigator on the research collaboration with Ridley and Grabowski summarized in “Developing Drugs for Developing Countries” (Health Affairs, March/April 2006) which led to the Sec. 524 amendment in the Food and Drug Administration Amendments Act of 2007. The article recommended, and the legislation made into law, a new
incentive for neglected tropical disease medicines: the priority review voucher (PRV). A PRV is awarded for US registration of a new medicine (new chemical, biological) for a voucher-eligible
isease (19 high burden and emergent diseases including TB, malaria and Ebola). An awarded voucher is exercised on a second drug that receives priority review as a reward for registration of the disease-eligible drug. FDA awarded the first voucher to Coartem® in 2009 and 13 vouchers have been awarded as of February 2017. The PRV program was amended in 2012 and again in 2016 to make pediatric cancer medicines and rare pediatric diseases voucher eligible. 4 vouchers have been awarded for neglected tropical diseases and 9 for other pediatric voucher-eligible diseases.
Dr. Julio Martin
GSK R&D, Tres Cantos (Spain)
Head of Kinetoplastid Biology, Director
I am currently working at the Kinetoplastid Discovery Performance Unit of GSK R&D at Tres Cantos (Spain). Our remit is to discover and develop new chemical entities for the treatment of human diseases caused by kinetoplastid parasites such as Leishmania and Trypanosoma. Our strategy is based on open innovation and collaborative research. Formerly, I have been responsible of ultra-HTS campaigns from screen development to dose-response and preliminary SAR. Likewise, I have been engaged in the development and implementation of new statistical tools and assay technologies for the improvement of HTS efficiency. I have explored label-free technologies for the screening of small molecules in protein and cellular assays in a joint collaboration with external companies.
I hold a PhD degree in Biochemistry from University of Madrid, where I acquired background and expertise on protein chemistry and enzymology. Prior to my current position, I worked at the R&D Department of Glaxo, where I managed programmes for discovery of new antimicrobial leads.
Cecilia Inés Centurión Founder Chagas Disease Alliance (2006)
Granddaughter and daughter of people affected by Chagas disease
Founder Chagas Disease Alliance (2006)- for the Hispanic community, social network of people living with the problem of Chagas. Founder of FINDECHAGAS (2010) - International Federation of Associations of People living with Chagas disease.
Member of the Board of Directors of the Carlos Chagas Association for active medical surveillance of Chagas disease (founded in 2009).Activist for Human Rights violated by the omission of the prevention of the disease of Chagas..
B. Fenton (“Lee”) Hall, MD, PhD
Lee Hall is Chief of the Parasitology and International Programs Branch (PIPB) in the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). PIPB supports research to better understand, diagnose, treat and prevent parasitic diseases, especially those that cause the greatest global burden. DMID’s R&D programs cover a variety of infectious diseases, and range from basic research, target identification and validation to translational research and development activities to clinical and field evaluation of promising interventional strategies and candidates domestically and overseas. Over the past 25 years Dr. Hall has assumed positions of increasing responsibility and leadership for innovative R&D in tropical medicine and global health. He has served on numerous committees and review panels for NIH, federal and international activities involving biomedical R&D, tropical medicine, and global health, and has chaired and participated in numerous symposia on these issues at national and international meetings. From 2010 to 2013 he served as a Member-at-Large on the Steering Committee of the Decade of Vaccines Collaboration, and since 2013 he has served as the NIAID Representative for the Decade of Vaccines Secretariat. Dr. Hall received his AB from Harvard College, and his MD and PhD in Immunology from the New York University School of Medicine. He completed his residency in Internal Medicine at the Johns Hopkins Hospital, and infectious diseases subspecialty training at the NIH and Yale University School of Medicine. He is a Fellow of the Infectious Diseases Society of America.